Listed

AMN Healthcare Services Inc: Form 10-Q for the period ended Mar 31, 2024

Filed with the SEC on May 10, 2024 and accepted by EDGAR at May 9, 2024, 18:05 ET.

Share

Management's discussion and analysis

As filed, 36,145 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on February 22, 2024 (“2023 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.

Overview of Our Business

We provide technology-enabled healthcare workforce solutions and staffing services to healthcare organizations across the nation. The Company provides access to a comprehensive network of healthcare professionals through its recruitment strategies and breadth of career opportunities. The Company helps providers optimize their workforce to reduce complexity and increase efficiency. The Company’s total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, permanent placement, executive search, vendor management systems, recruitment process outsourcing, predictive modeling, language services, revenue cycle solutions, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools and many other healthcare settings.

We conduct business through three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. For the three months ended March 31, 2024, we recorded revenue of $820.9 million, as compared to $1,126.2 million for the same period last year.

Nurse and allied solutions segment revenue comprised 63% and 73% of total consolidated revenue for the three months ended March 31, 2024 and 2023, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all the temporary and permanent nursing and allied staffing needs of a client. We also provide revenue cycle solutions, which include skilled labor solutions for remote medical coding, clinical documentation improvement, case management, and clinical data registry, and provide auditing and advisory services. A majority of our placements in this segment are under our managed services solution, however, we also provide traditional direct nurse and allied healthcare staffing solutions of variable assignment lengths.

Physician and leadership solutions segment revenue comprised 23% and 15% of total consolidated revenue for the three months ended March 31, 2024 and 2023, respectively. Through our physician and leadership solutions segment, we place physicians of all specialties, as well as dentists and advanced practice providers, with clients on a temporary basis, generally as independent contractors. We also recruit physicians and healthcare leaders for permanent placement and place interim leaders and executives across all healthcare settings. The interim healthcare leaders and executives we place are typically placed on contracts with assignment lengths ranging from a few days to one year.

Technology and workforce solutions segment revenue comprised 14% and 12% of total consolidated revenue for both of the three months ended March 31, 2024 and 2023, respectively. Through our technology and workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) language services, (2) software-as-a-service (“SaaS”)-based VMS technologies through which our clients can self-manage the procurement of contingent clinical labor and their internal float pool, (3) workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology, and (4) recruitment process outsourcing services in which we recruit, hire and/or onboard permanent clinical and nonclinical positions on behalf of our clients.

Operating Metrics

In addition to our consolidated and segment financial results, we monitor the following key metrics to help us evaluate our results of operations and financial condition and make strategic decisions. We believe this information is useful in understanding our operational performance and trends affecting our businesses.

  • Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period, which is used by management as a measure of volume in our nurse and allied solutions segment;
  • Bill rates represent the hourly straight-time rates that we bill to clients, which are an indicator of labor market trends and costs within our nurse and allied solutions segment;
  • Billable hours represent hours worked by our healthcare professionals that we are able to bill on client engagements, which are used by management as a measure of volume in our nurse and allied solutions segment;
  • Days filled is calculated by dividing total locum tenens hours filled during the period by eight hours, which is used by management as a measure of volume in our locum tenens business within our physician and leadership solutions segment;
  • Revenue per day filled is calculated by dividing revenue of our locum tenens business by days filled for the period, which is an indicator of labor market trends and costs in our locum tenens business within our physician and leadership solutions segment; and
  • Minutes represent the time-based utilization of interpretation services that we are able to bill our clients, which are used by management as a measure of volume in our language services business within our technology and workforce solutions segment.

Recent Trends

From late 2020 through most of 2022, the COVID-19 pandemic resulted in historically high demand for and utilization of our nurses, allied healthcare professionals and vendor-neutral VMS technologies supporting the placement of these professionals. Since 2022, healthcare organizations have aggressively hired permanent staff and focused on cost containment and alternative staffing models that enable them to reduce utilization of contingent labor. As a result, industry demand and demand in our travel nurse business has declined significantly to below pre-pandemic levels and we saw this trend continue in the first quarter of 2024. In our allied staffing business, demand continues to be above pre-pandemic levels, and certain specialties such as therapy and imaging are up significantly year over year, offsetting the decline in laboratory and other specialties involved in treating COVID-19 patients.

In our nurse and allied solutions segment, we have seen a decrease in overall staffing volume from prior year and prior quarter primarily due to lower travel nurse demand. Bill rates in the first quarter were relatively flat to prior quarter, but down year-over-year.

In our physician and leadership solutions segment, demand for our locum tenens staffing business declined from prior year and prior quarter. Certified registered nurse anesthetists (CRNAs) continue to be the largest specialty for our locum tenens staffing business. Revenue per day filled increased in the first quarter as compared to the prior year and prior quarter. Demand for our interim leadership business is leveling out after several quarters of decline. Demand for our physician permanent placement and executive search businesses continues to be soft as some healthcare organizations streamlined leadership roles, deferred hiring decisions, or increased insourcing.

In our technology and workforce solutions segment, our language services business continued to experience increased utilization in our existing clients and growth from new clients. Volumes in our VMS business followed similar trends, although to a greater extent, as our nurse and allied solutions segment, declining from historic highs. Bill rates continued to decrease in the first quarter.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, contingent consideration (“earn-out”) liabilities associated with acquisitions, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. There have been no material changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in our 2023 Annual Report.

Results of Operations

The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) physician and leadership solutions, and (3) technology and workforce solutions. The MSDR acquisition impacts the comparability of the results between the three months ended March 31, 2024 and 2023. See additional information in the accompanying Note (2), “Acquisitions.” Our historical results are not necessarily indicative of our future results of operations.

Unaudited Condensed Consolidated Statements of Operations:

Three Months Ended March 31, 2024 2023
Revenue 100.0% 100.0%
Cost of revenue 68.6 67.2
Gross profit 31.4 32.8
Selling, general and administrative 21.3 18.3
Depreciation and amortization 5.2 3.3
Income from operations 4.9 11.2
Interest expense, net, and other 2.1 1.0
Income before income taxes 2.8 10.2
Income tax expense 0.7 2.7
Net income 2.1% 7.5%

Comparison of Results for the Three Months Ended March 31, 2024 to the Three Months Ended March 31, 2023

Revenue. Revenue decreased 27% to $820.9 million for the three months ended March 31, 2024 from $1,126.2 million for the same period in 2023, attributable to a decline in organic revenue across our segments with the greatest decline in our nurse and allied solutions segment.

Nurse and allied solutions segment revenue decreased 37% to $519.3 million for the three months ended March 31, 2024 from $824.5 million for the same period in 2023. The $305.2 million decrease was primarily attributable to a 24% decrease in the average number of travelers on assignment, an approximately 15% decrease in the average bill rate, and a 3% decrease in billable hours.

Physician and leadership solutions segment revenue increased 14% to $188.8 million for the three months ended March 31, 2024 from $165.8 million for the same period in 2023. The $23.0 million increase was attributable to higher revenue in our locum tenens business, which was partially offset by lower revenue in our interim leadership, physician permanent placement and executive search businesses. Revenue in our locum tenens business grew approximately 36% during the three months ended March 31, 2024 primarily due to additional revenue of $37.1 million in connection with the MSDR acquisition and a 10% increase in the revenue per day filled on an organic basis, partially offset by an 8% decrease in the number of days filled on an organic basis. Our interim leadership business experienced a 25% decline and our physician permanent placement and executive search businesses declined 29% during the three months ended March 31, 2024, primarily due to lower demand.

Technology and workforce solutions segment revenue decreased 17% to $112.8 million for the three months ended March 31, 2024 from $136.0 million for the same period in 2023. The $23.2 million decrease was primarily attributable to a decline within our VMS and outsourced solutions businesses, partially offset by growth within our language services business. Revenue for our VMS business declined 46% for similar reasons as nurse and allied solutions segment revenue and our outsourced solutions business experienced a 49% decline primarily due to lower demand, while our language services business grew 16% primarily due to a 19% increase in minutes during the three months ended March 31, 2024.

For the three months ended March 31, 2024 and 2023, revenue under our MSP arrangements comprised approximately 48% and 57% of our consolidated revenue, 70% and 74% of our nurse and allied solutions segment revenue, 13% and 21% of our physician and leadership solutions segment revenue, and 3% and 2% of our technology and workforce solutions segment revenue, respectively.

Gross Profit. Gross profit decreased 30% to $257.5 million for the three months ended March 31, 2024 from $368.8 million for the same period in 2023, representing gross margins of 31.4% and 32.8%, respectively. The decline in consolidated gross margin for the three months ended March 31, 2024, as compared to the same period in 2023, was primarily due to (1) a lower margin in our technology and workforce solutions segment primarily due to a change in sales mix resulting from lower revenue in our VMS business and its higher margins as compared to our other businesses within the segment and (2) lower margins in our nurse and allied solutions and physician and leadership solutions segments driven by higher clinician compensation. The overall decline was partially offset by a change in sales mix resulting from lower revenue in our nurse and allied solutions segment. Gross margin by reportable segment for the three months ended March 31, 2024 and 2023 was 25.1% and 25.9% for nurse and allied solutions, 31.6% and 35.2% for physician and leadership solutions, and 59.9% and 71.4% for technology and workforce solutions, respectively.

Selling, General and Administrative Expenses. Selling, general and administrative (“SG&A”) expenses were $174.8 million, representing 21.3% of revenue, for the three months ended March 31, 2024, as compared to $205.6 million, representing 18.3% of revenue, for the same period in 2023. The decrease in SG&A expenses was primarily due to $17.1 million of lower employee compensation and benefits (inclusive of share-based compensation), a $2.9 million decrease in the provision for expected credit losses, and an approximately $7.0 million decrease in other expenses associated with our revenue decline. The year-over-year increase in SG&A expenses in our physician and leadership solutions segment was driven by $7.5 million of additional SG&A expenses from the MSDR acquisition, partially offset by the aforementioned decreases. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

(In Thousands)

Three Months Ended March 31, 2024 2023
Nurse and allied solutions $77,081 $99,997
Physician and leadership solutions 37,348 33,208
Technology and workforce solutions 25,041 31,343
Unallocated corporate overhead 27,633 30,733
Share-based compensation 7,739 10,318
$174,842 $205,599

Depreciation and Amortization Expenses. Amortization expense increased 15% to $24.9 million for the three months ended March 31, 2024 from $21.7 million for the same period in 2023, primarily attributable to additional amortization expense related to the intangible assets acquired in the MSDR acquisition. Depreciation expense (exclusive of depreciation included in cost of revenue) increased 12% to $17.8 million for the three months ended March 31, 2024 from $15.9 million for the same period in 2023, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing technology investments to support our tech-centric total talent solutions initiatives and to optimize our internal front and back-office systems. Additionally, $1.8 million and $1.3 million of depreciation expense for our language services business is included in cost of revenue for the three months ended March 31, 2024 and 2023, respectively.

Interest Expense, Net, and Other. Interest expense, net, and other was $16.6 million during the three months ended March 31, 2024 as compared to $10.3 million for the same period in 2023. The increase was primarily due to a higher average debt outstanding balance during the three months ended March 31, 2024.

Income Tax Expense. Income tax expense was $6.0 million for the three months ended March 31, 2024 as compared to $31.3 million for the same period in 2023, reflecting effective income tax rates of 26% and 27% for these periods, respectively. The decrease in the effective income tax rate was primarily attributable to the recognition of $2.4 million of net discrete tax benefit during the three months ended March 31, 2024 compared to a $0.8 million net discrete tax benefit during the same period in 2023, in relation to income before income taxes of $23.3 million and $115.4 million for the three months ended March 31, 2024 and 2023, respectively. We currently estimate our annual effective tax rate to be approximately 31% for 2024. The 26% effective tax rate for the three months ended March 31, 2024 differs from our estimated annual effective tax rate of 31% primarily due to certain discrete tax benefits recognized during the three months ended March 31, 2024, in relation to income before income taxes.

Liquidity and Capital Resources

In summary, our cash flows were:

(In Thousands)

Three Months Ended March 31, 2024 2023
Net cash provided by operating activities $81,386 $43,434
Net cash used in investing activities (21,399) (32,431)
Net cash used in financing activities (38,973) (44,457)
Net increase (decrease) in cash, cash equivalents and restricted cash $21,014 $(33,454)

Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and senior notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities and senior notes.

As of March 31, 2024, (1) $425.0 million was drawn with $304.2 million of available credit under our $750.0 million secured revolving credit facility (the “Senior Credit Facility”), (2) the aggregate principal amount of our 4.625% senior notes due 2027 (the “2027 Notes”) outstanding was $500.0 million, and (3) the aggregate principal amount of our 4.000% senior notes due 2029 (the “2029 Notes”) outstanding was $350.0 million. We describe in further detail our Amended Credit Agreement (as defined below), under which the Senior Credit Facility is governed, the 2027 Notes, and the 2029 Notes in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2023 Annual Report.

As of March 31, 2024, the total of our contractual obligations under operating leases with initial terms in excess of one year was $55.3 million. We describe in further detail our operating lease arrangements in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (5), Leases” of our 2023 Annual Report. We also have various obligations and working capital requirements, such as certain tax and legal matters, contingent consideration and other liabilities, that are recorded on our consolidated balance sheets. See additional information in the accompanying Note (7), “Fair Value Measurement,” Note (8), “Income Taxes,” Note (9), “Commitments and Contingencies,” and Note (10), “Balance Sheet Details.”

In addition to our cash requirements, we have a share repurchase program authorized by our board of directors, which does not require the purchase of any minimum number of shares and may be suspended or discontinued at any time. See additional information in the accompanying Part II, Item 2, “Unregistered Sales of Equity Securities and Use of Proceeds.”

We believe that cash generated from operations and available borrowings under the Senior Credit Facility will be sufficient to fund our operations and liquidity requirements, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under the Senior Credit Facility or other borrowings under our Amended Credit Agreement (as defined below), bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.

Operating Activities

Net cash provided by operating activities for the three months ended March 31, 2024 was $81.4 million, compared to $43.4 million for the same period in 2023. The increase in net cash provided by operating activities was primarily attributable to (1) a decrease in accounts receivable and subcontractor receivables between periods of $106.9 million primarily due to declines in revenue and associate vendor usage during the three months ended March 31, 2024 along with timing of collections, and (2) an increase in accrued compensation and benefits between periods of $64.7 million primarily due to bonuses and commissions that were paid during the three months ended March 31, 2023. The overall increase in net cash provided by operating activities was partially offset by (1) a decrease in net income excluding non-cash expenses of $92.7 million primarily due to a decline in segment operating income across our segments, (2) a decrease in accounts payable and accrued expenses between periods of $23.4 million primarily due to a decline in associate vendor usage and timing of payments, and (3) a decrease in other liabilities between periods of $17.6 million primarily due to an increase in income taxes payable during the prior year resulting from the timing of income tax payments. Our Days Sales Outstanding (“DSO”) was 64 days at March 31, 2024, 70 days at December 31, 2023, and 55 days at March 31, 2023.

Investing Activities

Net cash used in investing activities for the three months ended March 31, 2024 was $21.4 million, compared to net cash used in investing activities of $32.4 million for the same period in 2023. The decrease was primarily due to $4.5 million of payments to fund the deferred compensation plan during the three months ended March 31, 2024, as compared to $17.0 million of payments during the three months ended March 31, 2023. In addition, capital expenditures were $18.1 million and $17.5 million for the three months ended March 31, 2024 and 2023, respectively.

Financing Activities

Net cash used in financing activities during the three months ended March 31, 2024 was $39.0 million, due to repayments of $50.0 million under the Senior Credit Facility and $4.0 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards, partially offset by borrowings of $15.0 million under the Senior Credit Facility. Net cash used in financing activities during the three months ended March 31, 2023 was $44.5 million, due to (1) $174.7 million paid in connection with the repurchase of our common stock, (2) repayments of $70.0 million under the Senior Credit Facility, (3) $6.1 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards, and (4) $3.6 million payment of financing costs in connection with the Third Amendment (as defined below), all of which was partially offset by borrowings of $210.0 million under the Senior Credit Facility.

Amended Credit Agreement

On February 10, 2023, we entered into the third amendment to our credit agreement (the “Third Amendment”). The Third Amendment (together with the credit agreement as amended to date, collectively, the “Amended Credit Agreement”) provides for, among other things, an increase to the revolving commitments under the Senior Credit Facility to $750.0 million and an extension of the maturity date of the Amended Credit Agreement to February 10, 2028. Our obligations under the Amended Credit Agreement are secured by substantially all of our assets. We describe in further detail the terms of the Amended Credit Agreement in Part II, Item 8, “Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (8), Notes Payable and Credit Agreement” of our 2023 Annual Report.

Letters of Credit

At March 31, 2024, we maintained outstanding standby letters of credit totaling $21.3 million as collateral in relation to our workers’ compensation insurance agreements and a corporate office lease agreement. Of the $21.3 million of outstanding letters of credit, we have collateralized $0.6 million in cash and cash equivalents and the remaining $20.8 million is collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2023 totaled $21.3 million.

Recent Accounting Pronouncements

In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which expands the breadth and frequency of reportable segment disclosure requirements, primarily though enhanced disclosures about significant segment expenses. The new guidance requires public entities to disclose, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), the amount and composition of other segment items by reportable segment, any additional measures of a segment’s profit or loss used by the CODM when assessing performance and deciding how to allocate resources, and the CODM’s title and position. Additionally, public entities will be required to provide in interim periods all disclosures about a reportable segment’s profit or loss that are currently required annually by Topic 280. This standard is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting this standard on our disclosures.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which is intended to enhance the transparency and decision-usefulness of income tax disclosures. The new guidance addresses investor requests for enhanced income tax information primarily through requiring disclosure of additional information about and further disaggregation of the rate reconciliation and income taxes paid. This standard is effective on a prospective basis for fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting this standard on our disclosures.

There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of demand or supply trends, financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 2023 Annual Report and include but are not limited to:

  • the duration and extent to which hospitals and other healthcare entities adjust their utilization of temporary nurses and allied healthcare professionals, physicians, healthcare leaders and other healthcare professionals and workforce technology applications as a result of the labor market or economic conditions;
  • the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, telemedicine or otherwise, and successfully hire and retain permanent staff, which may negatively affect our revenue, results of operations, and cash flows;
  • the effects of the COVID-19 pandemic or any future pandemic or health crisis on our business, financial condition and results of operations;
  • the severity and duration of the impact the COVID-19 pandemic or any future pandemic or health crisis, the Great Resignation, economic downturns, inflation, recession or slow recoveries have on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered;
  • the extent to which a spike in the COVID-19 pandemic may disrupt our operations due to the unavailability of our employees or healthcare professionals because of illness, risk of illness, quarantines, travel restrictions, mandatory vaccination requirements, desire to travel and work on temporary assignments or other factors that limit our existing or potential workforce and pool of candidates;
  • the effects of economic downturns, inflation, recession or slow recoveries, which could result in less demand for our services, increased client initiatives designed to contain costs, including reevaluating their approach as it pertains to contingent labor and managed services programs;
  • any inability on our part to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs and requirements;
  • the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts;
  • the level of consolidation and concentration of buyers of healthcare workforce, staffing and technology solutions, which could affect the pricing of our services and our ability to mitigate concentration risk;
  • any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs, which could increase our operating costs and negatively affect our business and profitability;
  • any inability on our part to grow and operate our business profitably in compliance with federal and state regulation, including privacy laws, conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting;
  • any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
  • the effect of investigations, claims, and legal proceedings alleging medical malpractice, anti-competitive conduct, violations of employment, privacy and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;
  • any technology disruptions or our inability to implement new infrastructure and technology systems effectively may adversely affect our operating results and ability to manage our business effectively;
  • any failure to further develop and evolve our current workforce solutions technology offerings and capabilities, which may harm our business and/or impact our ability to compete with new technologies and competitors;
  • disruption to or failures of our SaaS-based or technology-enabled services, or our inability to adequately protect our intellectual property rights with respect to such technologies or sufficiently protect the privacy of personal information, could reduce client satisfaction, harm our reputation and negatively affect our business;
  • security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities;
  • any inability on our part to quickly and properly credential and match quality healthcare professionals with suitable placements, which may adversely affect demand for our services;
  • any inability on our part to continue to attract, develop and retain our sales and operations team members, which may deteriorate our operations;
  • our increasing dependence on third parties, including offshore vendors, for the execution of certain critical functions;
  • the loss of our key officers and management personnel, which could adversely affect our business and operating results;
  • any inability to consummate and effectively incorporate acquisitions into our business operations, which may adversely affect our long-term growth and our results of operations;
  • businesses we acquire may have liabilities or adverse operating issues, which could harm our operating results;
  • any increase to our business and operating risks as we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of client solutions;
  • any inability on our part to maintain our positive brand awareness and identity, which may adversely affect our results of operation;
  • the expansion of social media platforms presents new risks and challenges, which could cause damage to our brand reputation;
  • any recognition of an impairment to the substantial amount of goodwill or indefinite-lived intangibles on our balance sheet;
  • our indebtedness, which could adversely affect our ability to raise additional capital to fund operations, limit our ability to react to changes in the economy or our industry, and expose us to interest rate risk to the extent of any variable rate debt;
  • the terms of our debt instruments that impose restrictions on us that may affect our ability to successfully operate our business; and
  • the effect of significant adverse adjustments to our insurance-related accruals on our balance sheet, which could decrease our earnings or increase our losses and negatively impact our cash flows.

Market risk

As filed, 1,291 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three months ended March 31, 2024, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments and our investment portfolio. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three months ended March 31, 2024. A 100 basis point change in interest rates as of March 31, 2024 would not have resulted in a material effect on the fair value of our investment portfolio. For our investments that are classified as available-for-sale, unrealized gains or losses related to fluctuations in market volatility and interest rates are reflected within stockholders’ equity in accumulated other comprehensive loss in the consolidated balance sheets. Such unrealized gains or losses would be realized only if we sell the investments prior to maturity.

During the three months ended March 31, 2024, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.

Controls and procedures

As filed, 1,199 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of March 31, 2024 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 501 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2023 Annual Report. The risk factors described in our 2023 Annual Report are not the only risks we face. Factors we currently do not know, factors that we currently consider immaterial or factors that are not specific to us, such as general economic conditions, may also materially adversely affect our business or our consolidated operating results, financial condition or cash flows.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-01-01 to 2024-03-31$820.9mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2024-01-01 to 2024-03-31$563.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2024-01-01 to 2024-03-31$257.5mus-gaap:GrossProfit
Selling, general and administrative3 months2024-01-01 to 2024-03-31$174.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-01-01 to 2024-03-31$39.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-01-01 to 2024-03-31$16.6mus-gaap:InterestExpense
Income tax3 months2024-01-01 to 2024-03-31$6.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-01-01 to 2024-03-31$17.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-01-01 to 2024-03-31$0.45us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-01-01 to 2024-03-31$0.45us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-01-01 to 2024-03-3138,197,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2024-01-01 to 2024-03-31$81.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2024-01-01 to 2024-03-31$18.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2024-01-01 to 2024-03-31$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2024-03-31$50.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-03-31$790.7mus-gaap:AssetsCurrent
Total assetsAt period end2024-03-31$2.87bnus-gaap:Assets
Current liabilitiesAt period end2024-03-31$623.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-03-31$2.02bnus-gaap:Liabilities
Shareholders' equityAt period end2024-03-31$854.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001142750-24-000040. Last ingested by Listed: Nov 5, 2026, 17:59 ET. Listed shows no prices and gives no investment advice.